Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Baxter, Merck Divest To Middle East Firms
by Ann M. Thayer
November 8, 2010
| A version of this story appeared in
Volume 88, Issue 45
Merck Serono has sold its women’s health business, Théramex, to Israel’s Teva Pharmaceutical Industries. Teva will pay about $370 million and possible future milestones for products, R&D capabilities, and an active pharmaceutical ingredient facility. Théramex had sales of about $140 million in 2009. Meanwhile, Baxter International will sell its U.S. generic injectable drug business, which had 2009 sales of $170 million, to Jordan’s Hikma Pharmaceuticals for about $112 million. The deal includes a plant in Cherry Hill, N.J., and a distribution center in Memphis.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter